Report Detail
Clinical Laserthermia Systems AB (CLS B) - Product Pipeline Analysis, 2018 Update
- RnM2733833 |
- 07 January, 2019 |
- Global |
- 38 Pages |
- GlobalData |
- Medical Devices & Consumables
Summary
Clinical Laserthermia Systems AB (CLS) develops and markets systems and single-use instruments for the treatment of solid cancer tumors. The company's flagship product TRANBERG, a cancer immunotherapy system consists of a mobile laser unit and single-use products developed to perform a precise and safe treatment. It also comprises a laser applicator with introducer that is used for positioning of the fiber, depending on the tumor size. TRANBERG is developed for immune stimulating interstitial thermotherapy (imILT). CLS is also evaluating its products for treating focal laser ablation and other combined therapies. The company offers its products to hospitals and clinics. CLS is headquartered Lund, Sweden.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Clinical Laserthermia Systems AB
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Clinical Laserthermia Systems AB Company Overview 5
Clinical Laserthermia Systems AB Company Snapshot 5
Clinical Laserthermia Systems AB Pipeline Products and Ongoing Clinical Trials Overview 5
Clinical Laserthermia Systems AB – Pipeline Analysis Overview 8
Business Description 8
Clinical Laserthermia Systems AB - Key Facts 8
Clinical Laserthermia Systems AB - Major Products and Services 9
Clinical Laserthermia Systems AB Pipeline Products by Development Stage 10
Clinical Laserthermia Systems AB Ongoing Clinical Trials by Trial Status 14
Clinical Laserthermia Systems AB Pipeline Products Overview 16
CLS Cancer Immunotherapy System - Prostate Cancer 16
CLS Cancer Immunotherapy System - Prostate Cancer Product Overview 16
CLS Cancer Immunotherapy System - Prostate Cancer Clinical Trial 17
imILT Software 18
imILT Software Product Overview 18
imILT Software Clinical Trial 19
TRANBERG Cancer Immunotherapy System - Breast Cancer 20
TRANBERG Cancer Immunotherapy System - Breast Cancer Product Overview 20
TRANBERG Cancer Immunotherapy System - Breast Cancer Clinical Trial 21
TRANBERG Cancer Immunotherapy System - Pancreatic Cancer 22
TRANBERG Cancer Immunotherapy System - Pancreatic Cancer Product Overview 22
TRANBERG Cancer Immunotherapy System - Pancreatic Cancer Clinical Trial 23
TRANBERG Cancer Immunotherapy System - Skin Cancer 24
TRANBERG Cancer Immunotherapy System - Skin Cancer Product Overview 24
TRANBERG Cancer Immunotherapy System - Solid Cancers 25
TRANBERG Cancer Immunotherapy System - Solid Cancers Product Overview 25
TRANBERG Cancer Immunotherapy System - Solid Cancers Clinical Trial 26
Clinical Laserthermia Systems AB - Key Competitors 27
Clinical Laserthermia Systems AB - Key Employees 28
Clinical Laserthermia Systems AB - Key Employee Biographies 29
Clinical Laserthermia Systems AB - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Clinical Laserthermia Systems AB, Recent Developments 31
Jun 18, 2018: CLS receives new order for single use products from UTMB in the U.S., for treatment of early stage prostate cancer 31
Apr 19, 2018: First patients treated with CLS TRANBERG-system in the clinical study at Toronto General Hospital, Canada 31
Apr 19, 2018: CLS participates with hands-on workshop at the European Conference on Interventional Oncology 31
Apr 17, 2018: Clinical Laserthermia Systems and Toronto General Hospital Begin Clinical Study for MRI-Guided Laser Ablation Treatment of Prostate Cancer 32
Apr 11, 2018: Clinical Laserthermia Systems Exhibits MRI-Guided Laser Ablation System at Southwest Prostate Cancer Symposium 32
Apr 04, 2018: CLS quality processes received good marks by American authority FDA 32
Mar 16, 2018: CLS and Toronto General Hospital, Canada, carry out clinical study regarding MRI guided FLA treatment of prostate cancer 33
Mar 14, 2018: CLS receives new order for the TRANBERG-system from UTMB in the U.S. 33
Mar 08, 2018: CLS imILT treatment of pancreatic cancer shows positive trend regarding survival 33
Jan 02, 2018: CLS single use accessories evaluated by Laser Prostate Centers of America 34
Appendix 35
Methodology 35
About GlobalData 38
Contact Us 38
Disclaimer 38
Summary:
Get latest Market Research Reports on Clinical Laserthermia Systems AB (CLS B) . Industry analysis & Market Report on Clinical Laserthermia Systems AB (CLS B) is a syndicated market report, published as Clinical Laserthermia Systems AB (CLS B) - Product Pipeline Analysis, 2018 Update. It is complete Research Study and Industry Analysis of Clinical Laserthermia Systems AB (CLS B) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
